Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Neoplastic Stem Cells"" wg kryterium: Temat


Tytuł :
CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells.
Autorzy :
Surka C; Bristol-Myers Squibb, San Diego, CA.
Jin L; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Mbong N; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Lu CC; Bristol-Myers Squibb, San Diego, CA.
Jang IS; Bristol-Myers Squibb, San Diego, CA.
Rychak E; Bristol-Myers Squibb, San Diego, CA.
Mendy D; Bristol-Myers Squibb, San Diego, CA.
Clayton T; Bristol-Myers Squibb, San Diego, CA.
Tindall E; Bristol-Myers Squibb, San Diego, CA.
Hsu C; Bristol-Myers Squibb, San Diego, CA.
Fontanillo C; Bristol-Myers Squibb, San Diego, CA.
Tran E; Bristol-Myers Squibb, San Diego, CA.
Contreras A; Bristol-Myers Squibb, San Diego, CA.
Ng SWK; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Matyskiela M; Bristol-Myers Squibb, San Diego, CA.
Wang K; Bristol-Myers Squibb, San Diego, CA.
Chamberlain P; Bristol-Myers Squibb, San Diego, CA.
Cathers B; Bristol-Myers Squibb, San Diego, CA.
Carmichael J; Bristol-Myers Squibb, San Diego, CA.
Hansen J; Bristol-Myers Squibb, San Diego, CA.
Wang JCY; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Department of Medicine, University of Toronto, Toronto, ON, Canada.; Division of Medical Oncology and Hematology, University Health Network, Toronto, ON, Canada.
Minden MD; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Department of Medicine, University of Toronto, Toronto, ON, Canada.; Division of Medical Oncology and Hematology, University Health Network, Toronto, ON, Canada.
Fan J; Bristol-Myers Squibb, San Francisco, CA; and.
Pierce DW; Bristol-Myers Squibb, San Francisco, CA; and.
Pourdehnad M; Bristol-Myers Squibb, San Francisco, CA; and.
Rolfe M; Bristol-Myers Squibb, San Diego, CA.
Lopez-Girona A; Bristol-Myers Squibb, San Diego, CA.
Dick JE; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
Lu G; Bristol-Myers Squibb, San Diego, CA.
Pokaż więcej
Źródło :
Blood [Blood] 2021 Feb 04; Vol. 137 (5), pp. 661-677.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :
Molecular Targeted Therapy*
Acetamides/*pharmacology
Adaptor Proteins, Signal Transducing/*antagonists & inhibitors
Isoindoles/*pharmacology
Leukemia, Myeloid, Acute/*pathology
Neoplasm Proteins/*antagonists & inhibitors
Neoplastic Stem Cells/*drug effects
Piperidones/*pharmacology
Ubiquitin-Protein Ligases/*antagonists & inhibitors
Acetamides/therapeutic use ; Animals ; CRISPR-Cas Systems ; Cell Line, Tumor ; Humans ; Isoindoles/therapeutic use ; Mice ; Mice, Inbred NOD ; Mice, SCID ; Models, Molecular ; Neoplastic Stem Cells/enzymology ; Nuclear Factor 45 Protein/physiology ; Nuclear Factor 90 Proteins/physiology ; Peptide Termination Factors/metabolism ; Piperidones/therapeutic use ; Proteasome Endopeptidase Complex/metabolism ; Protein Conformation ; Protein Processing, Post-Translational/drug effects ; Proteolysis ; Small Molecule Libraries ; Stress, Physiological ; TOR Serine-Threonine Kinases/physiology ; U937 Cells ; Ubiquitination/drug effects ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
RUNX1 and CBFβ-SMMHC transactivate target genes together in abnormal myeloid progenitors for leukemia development.
Autorzy :
Zhen T; Oncogenesis and Development Section, National Human Genome Research Institute, and.
Cao Y; Laboratory of Epigenome Biology, Systems Biology Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Ren G; Laboratory of Epigenome Biology, Systems Biology Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Zhao L; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA.
Hyde RK; Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE; and.
Lopez G; Oncogenesis and Development Section, National Human Genome Research Institute, and.
Feng D; Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD.
Alemu L; Oncogenesis and Development Section, National Human Genome Research Institute, and.
Zhao K; Laboratory of Epigenome Biology, Systems Biology Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Liu PP; Oncogenesis and Development Section, National Human Genome Research Institute, and.
Pokaż więcej
Źródło :
Blood [Blood] 2020 Nov 19; Vol. 136 (21), pp. 2373-2385.
Typ publikacji :
Journal Article; Research Support, N.I.H., Intramural
MeSH Terms :
Gene Expression Regulation, Leukemic*/drug effects
Transcriptional Activation*
Cell Transformation, Neoplastic/*genetics
Core Binding Factor Alpha 2 Subunit/*physiology
Leukemia, Experimental/*genetics
Myeloid Cells/*metabolism
Neoplasm Proteins/*physiology
Neoplastic Stem Cells/*metabolism
Oncogene Proteins, Fusion/*physiology
Animals ; Core Binding Factor Alpha 2 Subunit/deficiency ; Core Binding Factor Alpha 2 Subunit/genetics ; Gene Knock-In Techniques ; Humans ; Leukemia, Experimental/etiology ; Mice, 129 Strain ; Mice, Inbred C57BL ; Mice, Knockout ; Myeloid Cells/cytology ; Neoplastic Stem Cells/cytology ; Oncogene Proteins, Fusion/genetics ; Poly I-C/pharmacology ; RNA, Messenger/biosynthesis ; RNA, Messenger/genetics ; RNA, Neoplasm/biosynthesis ; RNA, Neoplasm/genetics ; RNA-Seq ; Single-Cell Analysis
Czasopismo naukowe
Tytuł :
The miR-185/PAK6 axis predicts therapy response and regulates survival of drug-resistant leukemic stem cells in CML.
Autorzy :
Lin H; Terry Fox Laboratory, British Columbia Cancer Research Institute, Vancouver, BC, Canada.; Department of Medicine.
Rothe K; Terry Fox Laboratory, British Columbia Cancer Research Institute, Vancouver, BC, Canada.; Department of Medical Genetics.
Chen M; Terry Fox Laboratory, British Columbia Cancer Research Institute, Vancouver, BC, Canada.
Wu A; Terry Fox Laboratory, British Columbia Cancer Research Institute, Vancouver, BC, Canada.; Department of Medicine.
Babaian A; Terry Fox Laboratory, British Columbia Cancer Research Institute, Vancouver, BC, Canada.; Department of Medical Genetics.
Yen R; Terry Fox Laboratory, British Columbia Cancer Research Institute, Vancouver, BC, Canada.; Department of Medicine.
Zeng J; Terry Fox Laboratory, British Columbia Cancer Research Institute, Vancouver, BC, Canada.
Ruschmann J; Terry Fox Laboratory, British Columbia Cancer Research Institute, Vancouver, BC, Canada.
Petriv OI; Center for High-Throughput Biology, and.; Department of Physics and Astronomy, University of British Columbia, Vancouver, BC, Canada.
O'Neill K; Terry Fox Laboratory, British Columbia Cancer Research Institute, Vancouver, BC, Canada.
Maetzig T; Terry Fox Laboratory, British Columbia Cancer Research Institute, Vancouver, BC, Canada.
Knapp DJHF; Terry Fox Laboratory, British Columbia Cancer Research Institute, Vancouver, BC, Canada.; Department of Medicine.
Nakamichi N; Terry Fox Laboratory, British Columbia Cancer Research Institute, Vancouver, BC, Canada.
Brinkman R; Terry Fox Laboratory, British Columbia Cancer Research Institute, Vancouver, BC, Canada.; Department of Medical Genetics.
Birol I; Department of Medical Genetics.; Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Research Institute, Vancouver, BC, Canada; and.
Forrest DL; Department of Medicine.; Leukemia/Bone Marrow Transplant Program of British Columbia, Vancouver, BC, Canada.
Hansen C; Center for High-Throughput Biology, and.
Humphries RK; Terry Fox Laboratory, British Columbia Cancer Research Institute, Vancouver, BC, Canada.; Department of Medicine.
Eaves CJ; Terry Fox Laboratory, British Columbia Cancer Research Institute, Vancouver, BC, Canada.; Department of Medicine.; Department of Medical Genetics.
Jiang X; Terry Fox Laboratory, British Columbia Cancer Research Institute, Vancouver, BC, Canada.; Department of Medicine.; Department of Medical Genetics.
Pokaż więcej
Źródło :
Blood [Blood] 2020 Jul 30; Vol. 136 (5), pp. 596-609.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Drug Resistance, Neoplasm/*genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*genetics
MicroRNAs/*genetics
Neoplastic Stem Cells/*pathology
p21-Activated Kinases/*genetics
Animals ; Gene Expression Regulation, Leukemic/genetics ; Heterografts ; Humans ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/metabolism ; Mice ; Mice, SCID ; MicroRNAs/metabolism ; Neoplastic Stem Cells/metabolism ; Protein Kinase Inhibitors/therapeutic use ; Signal Transduction/physiology ; p21-Activated Kinases/metabolism
Czasopismo naukowe
Tytuł :
Myc-Miz1 signaling promotes self-renewal of leukemia stem cells by repressing Cebpα and Cebpδ.
Autorzy :
Zhang L; Department of Biology, College of Life Sciences, Shanghai Normal University, Shanghai, People's Republic of China.; Oncology Institute, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL.
Li J; Department of Biology, College of Life Sciences, Shanghai Normal University, Shanghai, People's Republic of China.
Xu H; Department of Biology, College of Life Sciences, Shanghai Normal University, Shanghai, People's Republic of China.
Shao X; Department of Biology, College of Life Sciences, Shanghai Normal University, Shanghai, People's Republic of China.
Fu L; Department of Biology, College of Life Sciences, Shanghai Normal University, Shanghai, People's Republic of China.
Hou Y; Department of Biology, College of Life Sciences, Shanghai Normal University, Shanghai, People's Republic of China.
Hao C; Department of Biology, College of Life Sciences, Shanghai Normal University, Shanghai, People's Republic of China.
Li W; Department of Gynaecology and Obstetrics, Lanzhou University Second Hospital, Lanzhou, China.
Joshi K; Oncology Institute, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL.
Wei W; Oncology Institute, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL.
Xu Y; Department of Biology, College of Life Sciences, Shanghai Normal University, Shanghai, People's Republic of China.
Zhang F; Department of Biology, College of Life Sciences, Shanghai Normal University, Shanghai, People's Republic of China.
Dai S; Department of Biology, College of Life Sciences, Shanghai Normal University, Shanghai, People's Republic of China.
Breslin P; Oncology Institute, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL.; Department of Biology and.; Department of Cell and Molecular Physiology, Loyola University Chicago, Chicago, IL; and.
Zhang J; Oncology Institute, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL.; Department of Pathology, Loyola University Medical Center, Maywood, IL.
Zhang J; Department of Biology, College of Life Sciences, Shanghai Normal University, Shanghai, People's Republic of China.
Pokaż więcej
Źródło :
Blood [Blood] 2020 Apr 02; Vol. 135 (14), pp. 1133-1145.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
CCAAT-Enhancer-Binding Protein-delta/*metabolism
CCAAT-Enhancer-Binding Proteins/*metabolism
Leukemia, Myeloid, Acute/*metabolism
Neoplastic Stem Cells/*metabolism
Protein Inhibitors of Activated STAT/*metabolism
Proto-Oncogene Proteins c-myc/*metabolism
Ubiquitin-Protein Ligases/*metabolism
Animals ; Cell Self Renewal ; Female ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/pathology ; Male ; Mice, Inbred C57BL ; Neoplastic Stem Cells/cytology ; Neoplastic Stem Cells/pathology ; Point Mutation ; Proto-Oncogene Proteins c-myc/genetics ; Signal Transduction
Czasopismo naukowe
Tytuł :
A human SIRPA knock-in xenograft mouse model to study human hematopoietic and cancer stem cells.
Autorzy :
Jinnouchi F; Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
Yamauchi T; Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.; Center for Cellular and Molecular Medicine, Kyushu University Hospital, Fukuoka, Japan.
Yurino A; Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
Nunomura T; Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
Nakano M; Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
Iwamoto C; Department of Surgery and Oncology, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
Obara T; Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
Miyawaki K; Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.; Department of Pathology, Kurume University School of Medicine, Kurume, Japan; and.
Kikushige Y; Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
Kato K; Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
Maeda T; Center for Cellular and Molecular Medicine, Kyushu University Hospital, Fukuoka, Japan.
Miyamoto T; Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
Baba E; Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
Akashi K; Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
Takenaka K; Hematology, Clinical Immunology, and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime, Japan.
Pokaż więcej
Źródło :
Blood [Blood] 2020 May 07; Vol. 135 (19), pp. 1661-1672.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Hematopoiesis*
Phagocytosis*
Antigens, Differentiation/*physiology
Colonic Neoplasms/*pathology
Hematopoietic Stem Cells/*pathology
Leukemia, Myeloid, Acute/*pathology
Neoplastic Stem Cells/*pathology
Receptors, Immunologic/*physiology
Animals ; Apoptosis ; Cell Proliferation ; Colonic Neoplasms/genetics ; Colonic Neoplasms/metabolism ; Female ; Gene Knock-In Techniques ; Hematopoietic Stem Cells/metabolism ; Humans ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/metabolism ; Male ; Mice ; Mice, Inbred C57BL ; Mice, Inbred NOD ; Neoplastic Stem Cells/metabolism ; Tumor Cells, Cultured ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
How I diagnose and treat NPM1-mutated AML.
Autorzy :
Falini B; Institute of Hematology, Centro Ricerche Emato-Oncologiche, Ospedale S. Maria della Misericordia, University of Perugia, Perugia, Italy.
Brunetti L; Institute of Hematology, Centro Ricerche Emato-Oncologiche, Ospedale S. Maria della Misericordia, University of Perugia, Perugia, Italy.
Martelli MP; Institute of Hematology, Centro Ricerche Emato-Oncologiche, Ospedale S. Maria della Misericordia, University of Perugia, Perugia, Italy.
Pokaż więcej
Źródło :
Blood [Blood] 2021 Feb 04; Vol. 137 (5), pp. 589-599.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Practice Patterns, Physicians'*
Leukemia, Myeloid, Acute/*diagnosis
Leukemia, Myeloid, Acute/*therapy
Nuclear Proteins/*genetics
Oncogene Proteins, Fusion/*genetics
Age Factors ; Aged ; Algorithms ; Allografts ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bone Marrow/pathology ; Bridged Bicyclo Compounds, Heterocyclic/administration & dosage ; Cell Lineage ; Clinical Trials as Topic ; Clonal Evolution ; Combined Modality Therapy ; Diagnosis, Differential ; Disease Management ; Female ; Gemtuzumab/administration & dosage ; Hematopoietic Stem Cell Transplantation ; Humans ; Leukemia, Myeloid, Acute/classification ; Leukemia, Myeloid, Acute/genetics ; Male ; Middle Aged ; Molecular Targeted Therapy ; Myelodysplastic Syndromes/chemically induced ; Myelodysplastic Syndromes/diagnosis ; Neoplastic Stem Cells/pathology ; Nuclear Proteins/antagonists & inhibitors ; Oncogene Proteins, Fusion/antagonists & inhibitors ; Patient Selection ; Remission Induction ; Risk Assessment ; Salvage Therapy ; Sulfonamides/administration & dosage ; fms-Like Tyrosine Kinase 3/genetics
Czasopismo naukowe
Tytuł :
IL-7R is essential for leukemia-initiating cell activity of T-cell acute lymphoblastic leukemia.
Autorzy :
González-García S; Department of Cell Biology and Immunology, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Madrid, Spain.
Mosquera M; Department of Cell Biology and Immunology, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Madrid, Spain.
Fuentes P; Department of Cell Biology and Immunology, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Madrid, Spain.
Palumbo T; Department of Cell Biology and Immunology, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Madrid, Spain.
Escudero A; Translational Research in Pediatric Oncology, Hematopoietic Transplantation and Cell Therapy, Instituto de Genética Médica y Molecular del Instituto de Investigación Sanitaria del Hospital Universitario La Paz (INGEMM-IdiPAZ), Madrid, Spain.
Pérez-Martínez A; Translational Research in Pediatric Oncology, Hematopoietic Transplantation and Cell Therapy, Instituto de Genética Médica y Molecular del Instituto de Investigación Sanitaria del Hospital Universitario La Paz (INGEMM-IdiPAZ), Madrid, Spain.; Pediatric Hemato-Oncology Service, Hospital Universitario La Paz, Madrid, Spain.; Department of Pediatrics, UAM, Madrid, Spain.
Ramírez M; Department of Pediatric Hematology and Oncology, Hospital Infantil Universitario Niño Jesús, UAM, Spain and.
Corcoran AE; Nuclear Dynamics Programme and Laboratory of Lymphocyte Signalling and Development, Babraham Institute, Babraham Research Campus, Cambridge, United Kingdom.
Toribio ML; Department of Cell Biology and Immunology, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Madrid, Spain.
Pokaż więcej
Źródło :
Blood [Blood] 2019 Dec 12; Vol. 134 (24), pp. 2171-2182.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Disease Susceptibility*
Neoplastic Stem Cells/*metabolism
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/*etiology
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/*metabolism
Receptors, Interleukin-7/*metabolism
Animals ; Antineoplastic Agents, Immunological/pharmacology ; Antineoplastic Agents, Immunological/therapeutic use ; Biomarkers ; Cell Line, Tumor ; Disease Models, Animal ; Gene Expression ; Hematopoietic Stem Cells/metabolism ; Humans ; Mice ; Neoplastic Stem Cells/pathology ; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy ; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/pathology ; Receptor, Notch1/genetics ; Receptor, Notch1/metabolism ; Receptors, Interleukin-7/genetics ; Signal Transduction/drug effects ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
A KLF4-DYRK2-mediated pathway regulating self-renewal in CML stem cells.
Autorzy :
Park CS; Department of Pathology and Immunology and.
Lewis AH; Department of Pathology and Immunology and.; Integrative Molecular and Biomedical Sciences Program, Baylor College of Medicine, Houston, TX.
Chen TJ; Department of Pathology and Immunology and.; Integrative Molecular and Biomedical Sciences Program, Baylor College of Medicine, Houston, TX.
Bridges CS; Department of Pathology and Immunology and.
Shen Y; Department of Pathology and Immunology and.; Integrative Molecular and Biomedical Sciences Program, Baylor College of Medicine, Houston, TX.
Suppipat K; Texas Children's Cancer and Hematology Center, Texas Children's Hospital, Houston, TX.
Puppi M; Department of Pathology and Immunology and.
Tomolonis JA; MD/PhD Program, Baylor College of Medicine, Houston, TX.
Pang PD; Integrative Molecular and Biomedical Sciences Program, Baylor College of Medicine, Houston, TX.
Mistretta TA; Department of Pathology and Immunology and.
Ma L; Department of Molecular, Cell, and Cancer Biology, University of Massachusetts Medical School, Worcester, MA.
Green MR; Department of Molecular, Cell, and Cancer Biology, University of Massachusetts Medical School, Worcester, MA.
Rau R; Department of Pediatrics-Oncology, Baylor College of Medicine, Houston, TX.
Lacorazza HD; Department of Pathology and Immunology and.
Pokaż więcej
Źródło :
Blood [Blood] 2019 Nov 28; Vol. 134 (22), pp. 1960-1972.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Signal Transduction*
Kruppel-Like Transcription Factors/*metabolism
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*metabolism
Neoplastic Stem Cells/*metabolism
Protein-Serine-Threonine Kinases/*metabolism
Protein-Tyrosine Kinases/*metabolism
Animals ; Cell Survival/drug effects ; Cell Survival/genetics ; Fusion Proteins, bcr-abl/genetics ; Fusion Proteins, bcr-abl/metabolism ; Gene Deletion ; Humans ; Kruppel-Like Transcription Factors/genetics ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology ; Mice ; Mice, Knockout ; Neoplastic Stem Cells/pathology ; Protein-Serine-Threonine Kinases/genetics ; Protein-Tyrosine Kinases/genetics ; Proto-Oncogene Proteins c-myc/genetics ; Proto-Oncogene Proteins c-myc/metabolism ; Tumor Suppressor Protein p53/genetics ; Tumor Suppressor Protein p53/metabolism ; Ubiquitin-Protein Ligases/genetics ; Ubiquitin-Protein Ligases/metabolism ; Vitamin K 3/pharmacology
Czasopismo naukowe
Tytuł :
A stemness screen reveals C3orf54/INKA1 as a promoter of human leukemia stem cell latency.
Autorzy :
Kaufmann KB; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
Garcia-Prat L; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
Liu Q; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
Ng SWK; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Takayanagi SI; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Regenerative Medicine Laboratories, Kyowa Hakko Kirin Co., Ltd., Tokyo, Japan.
Mitchell A; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
Wienholds E; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
van Galen P; Massachusetts General Hospital, Boston, MA.
Cumbaa CA; Krembil Research Institute, University Health Network, Toronto, ON, Canada.
Tsay MJ; Krembil Research Institute, University Health Network, Toronto, ON, Canada.
Pastrello C; Krembil Research Institute, University Health Network, Toronto, ON, Canada.
Wagenblast E; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
Krivdova G; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
Minden MD; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Department of Medical Biophysics.; Department of Medicine, and.
Lechman ER; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
Zandi S; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
Jurisica I; Krembil Research Institute, University Health Network, Toronto, ON, Canada.; Department of Medical Biophysics.; Department of Computer Sciences, University of Toronto, Toronto, ON, Canada; and.
Wang JCY; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Department of Medicine, and.; Division of Medical Oncology and Hematology, University Health Network, Toronto, ON, Canada.
Xie SZ; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
Dick JE; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
Pokaż więcej
Źródło :
Blood [Blood] 2019 May 16; Vol. 133 (20), pp. 2198-2211. Date of Electronic Publication: 2019 Feb 22.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Gene Expression Regulation, Leukemic*
Intracellular Signaling Peptides and Proteins/*genetics
Leukemia, Myeloid, Acute/*genetics
Neoplastic Stem Cells/*metabolism
Animals ; Cell Cycle Checkpoints ; Cell Line, Tumor ; Female ; Humans ; Leukemia, Myeloid, Acute/pathology ; Male ; Mice, Inbred NOD ; Neoplastic Stem Cells/cytology ; Neoplastic Stem Cells/pathology ; Up-Regulation ; p21-Activated Kinases/analysis
Czasopismo naukowe
Tytuł :
Extramedullary early T-cell precursor acute lymphoblastic lymphoma presenting as blast crisis of CML.
Autorzy :
Wang HY; University of California San Diego Health System.
Tzachanis D; University of California San Diego Health System.
Pokaż więcej
Źródło :
Blood [Blood] 2020 Aug 27; Vol. 136 (9), pp. 1112.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Blast Crisis/*diagnosis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*pathology
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/*diagnosis
Adult ; Antigens, CD/analysis ; Antineoplastic Agents/therapeutic use ; Biomarkers, Tumor/analysis ; Blast Crisis/etiology ; Humans ; In Situ Hybridization, Fluorescence ; Male ; Neoplastic Stem Cells/chemistry ; Neoplastic Stem Cells/pathology ; Philadelphia Chromosome ; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy ; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/etiology ; Protein Kinase Inhibitors/therapeutic use ; Retroperitoneal Space
Czasopismo naukowe
Tytuł :
Quantitative proteomics reveals specific metabolic features of acute myeloid leukemia stem cells.
Autorzy :
Raffel S; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM) GmbH, Heidelberg, Germany.; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.; DKFZ Center for Molecular Biology Heidelberg (DKFZ-ZMBH) Alliance, Heidelberg, Germany.; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
Klimmeck D; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM) GmbH, Heidelberg, Germany.; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.; DKFZ Center for Molecular Biology Heidelberg (DKFZ-ZMBH) Alliance, Heidelberg, Germany.
Falcone M; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM) GmbH, Heidelberg, Germany.; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.; DKFZ Center for Molecular Biology Heidelberg (DKFZ-ZMBH) Alliance, Heidelberg, Germany.
Demir A; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
Pouya A; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
Zeisberger P; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM) GmbH, Heidelberg, Germany.; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.; DKFZ Center for Molecular Biology Heidelberg (DKFZ-ZMBH) Alliance, Heidelberg, Germany.
Lutz C; Praxis für Hämatologie und Onkologie, Koblenz, Germany.
Tinelli M; Department of Orthopaedics and Trauma Surgery, Sinsheim Hospital, Sinsheim, Germany.
Bischel O; BG Trauma Center Ludwigshafen at Heidelberg University Hospital, Ludwigshafen, Germany.
Bullinger L; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.; Department of Hematology, Oncology and Tumorimmunology, Charité University Medicine, Berlin, Germany.
Thiede C; Medical Department 1, University Hospital Carl Gustav Carus, Dresden, Germany.
Flörcken A; Department of Hematology, Oncology and Tumorimmunology, Charité University Medicine, Berlin, Germany.
Westermann J; Department of Hematology, Oncology and Tumorimmunology, Charité University Medicine, Berlin, Germany.
Ehninger G; Medical Department 1, University Hospital Carl Gustav Carus, Dresden, Germany.
Ho AD; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
Müller-Tidow C; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
Gu Z; Division of Theoretical Bioinformatics, DKFZ, Heidelberg, Germany.
Herrmann C; Health Data Science Unit, Medical Faculty Heidelberg, and.; Bioquant Center, University of Heidelberg, Heidelberg, Germany.
Krijgsveld J; Genome Biology Unit, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.; Division of Proteomics of Stem Cells and Cancer, DKFZ, Heidelberg, Germany.; Medical Faculty, Heidelberg University, Heidelberg, Germany.
Trumpp A; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM) GmbH, Heidelberg, Germany.; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.; DKFZ Center for Molecular Biology Heidelberg (DKFZ-ZMBH) Alliance, Heidelberg, Germany.; German Cancer Consortium (DKTK); and.
Hansson J; Genome Biology Unit, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.; Lund Stem Cell Center, Division of Molecular Hematology, Lund University, Lund, Sweden.
Pokaż więcej
Źródło :
Blood [Blood] 2020 Sep 24; Vol. 136 (13), pp. 1507-1519.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Leukemia, Myeloid, Acute/*metabolism
Neoplastic Stem Cells/*metabolism
Animals ; Energy Metabolism ; Gene Expression Regulation, Leukemic ; Humans ; Leukemia, Myeloid, Acute/genetics ; Mice ; Proteome/genetics ; Proteome/metabolism ; Proteomics ; Transcriptome
Czasopismo naukowe
Tytuł :
Glucocorticoids enhance the antileukemic activity of FLT3 inhibitors in FLT3-mutant acute myeloid leukemia.
Autorzy :
Gebru MT; Department of Pediatrics.
Atkinson JM; Department of Pediatrics.
Young MM; Department of Pediatrics.
Zhang L; Department of Biochemistry and Molecular Biology.; Institute for Personalized Medicine.
Tang Z; Department of Pediatrics.
Liu Z; Department of Public Health Sciences, Pennsylvania State University College of Medicine, Hershey, PA.
Lu P; Center for Precision Health, School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX; and.
Dower CM; Department of Pediatrics.
Chen L; Department of Pediatrics.
Annageldiyev C; Department of Medicine, and.
Sharma A; Department of Pharmacology.
Imamura Kawasawa Y; Department of Pharmacology.; Department of Biochemistry and Molecular Biology.; Institute for Personalized Medicine.
Zhao Z; Center for Precision Health, School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX; and.; The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX.
Miller BA; Department of Pediatrics.
Claxton DF; Department of Medicine, and.
Wang HG; Department of Pediatrics.; Department of Pharmacology.
Pokaż więcej
Źródło :
Blood [Blood] 2020 Aug 27; Vol. 136 (9), pp. 1067-1079.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Glucocorticoids/*therapeutic use
Leukemia, Myeloid, Acute/*drug therapy
Neoplasm Proteins/*antagonists & inhibitors
Protein Kinase Inhibitors/*therapeutic use
fms-Like Tyrosine Kinase 3/*antagonists & inhibitors
Animals ; Anti-Inflammatory Agents/pharmacology ; Anti-Inflammatory Agents/therapeutic use ; Antineoplastic Agents/pharmacology ; Apoptosis Regulatory Proteins/biosynthesis ; Apoptosis Regulatory Proteins/genetics ; Bcl-2-Like Protein 11/biosynthesis ; Bcl-2-Like Protein 11/genetics ; Benzothiazoles/pharmacology ; Benzothiazoles/therapeutic use ; Computer Simulation ; Dexamethasone/pharmacology ; Dexamethasone/therapeutic use ; Drug Resistance, Neoplasm ; Drug Synergism ; Gene Expression Regulation, Leukemic/drug effects ; Glucocorticoids/pharmacology ; Humans ; Inflammation/genetics ; Mice ; Myeloid Cell Leukemia Sequence 1 Protein/biosynthesis ; Myeloid Cell Leukemia Sequence 1 Protein/genetics ; Neoplasm Proteins/biosynthesis ; Neoplasm Proteins/genetics ; Neoplastic Stem Cells/drug effects ; Phenylurea Compounds/pharmacology ; Phenylurea Compounds/therapeutic use ; Protein Kinase Inhibitors/pharmacology ; Selection, Genetic ; Transcriptome ; Tumor Cells, Cultured ; Xenograft Model Antitumor Assays ; fms-Like Tyrosine Kinase 3/genetics
Czasopismo naukowe
Tytuł :
Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers.
Autorzy :
Fagnan A; Unité 1170 (U1170), INSERM, Gustave Roussy, Université Paris Diderot, Villejuif, France.; Equipe Labellisée Ligue Nationale Contre le Cancer, Paris, France.
Bagger FO; University Children's Hospital Beider Basel (UKBB), Basel, Switzerland.; Department of Biomedicine, University of Basel, Basel, Switzerland.; Center for Genomic Medicine, Copenhagen University Hospital, Copenhagen, Denmark.; Swiss Institute of Bioinformatics, Basel, Basel, Switzerland.
Piqué-Borràs MR; University Children's Hospital Beider Basel (UKBB), Basel, Switzerland.; Department of Biomedicine, University of Basel, Basel, Switzerland.
Ignacimouttou C; Unité 1170 (U1170), INSERM, Gustave Roussy, Université Paris Diderot, Villejuif, France.; Equipe Labellisée Ligue Nationale Contre le Cancer, Paris, France.
Caulier A; Equipe d'Accueil (EA) 4666, Hématopoïèse et Immunologie (HEMATIM), Université de Picardie Jules Verne (UPJV), Amiens, France.; Service Hématologie Biologique, Centre Hospitalier Universitaire (CHU) Amiens, Amiens, France.
Lopez CK; Unité 1170 (U1170), INSERM, Gustave Roussy, Université Paris Diderot, Villejuif, France.; Equipe Labellisée Ligue Nationale Contre le Cancer, Paris, France.
Robert E; Unité 1170 (U1170), INSERM, Gustave Roussy, Université Paris Diderot, Villejuif, France.; Equipe Labellisée Ligue Nationale Contre le Cancer, Paris, France.
Uzan B; Unité Mixte de Recherche 967 (UMR 967), INSERM-Commissariat à l'Énergie Atomique et aux Énergies Alternatives (CEA)/Direction de la Recherche Fondamentale (DRF)/Institut de Biologie François Jacob (IBFJ)/Institut de Radiobiologie Cellulaire et Moléculaire (IRCM)/Laboratoire des cellules Souches Hématopoïétiques et des Leucémies (LSHL)-Université Paris-Diderot-Université Paris-Sud, Fontenay-aux-Roses, France.
Gelsi-Boyer V; U1068 and.; UMR7258, Centre de Recherche en Cancérologie de Marseille, Centre National de la Recherche Scientifique (CNRS)/INSERM/Institut Paoli Calmettes/Aix-Marseille Université, Marseille, France.
Aid Z; Unité 1170 (U1170), INSERM, Gustave Roussy, Université Paris Diderot, Villejuif, France.; Equipe Labellisée Ligue Nationale Contre le Cancer, Paris, France.
Thirant C; Unité 1170 (U1170), INSERM, Gustave Roussy, Université Paris Diderot, Villejuif, France.; Equipe Labellisée Ligue Nationale Contre le Cancer, Paris, France.
Moll U; Institute of Molecular Oncology, University Medical Center Göttingen, Göttingen, Germany.; Department of Pathology, Stony Brook University, Stony Brook, NY.
Tauchmann S; University Children's Hospital Beider Basel (UKBB), Basel, Switzerland.; Department of Biomedicine, University of Basel, Basel, Switzerland.
Kurtovic-Kozaric A; Clinical Center of the University of Sarajevo, University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
Maciejewski J; Department of Translational Hematology and Oncologic Research, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH.
Dierks C; Hämatologie, Onkologie und Stammzelltransplantation, Klinik für Innere Medizin I, Freiburg, Germany.
Spinelli O; UOC Ematologia, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII Hospital, Bergamo, Italy.
Salmoiraghi S; UOC Ematologia, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII Hospital, Bergamo, Italy.; FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy.
Pabst T; Department of Oncology, Inselspital, University Hospital Bern/University of Bern, Bern, Switzerland.
Shimoda K; Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Deleuze V; IGMM, University of Montpellier, CNRS, Montpellier, France.; Université de Paris, Laboratory of Excellence GR-Ex, Paris, France.
Lapillonne H; Centre de Recherche Saint Antoine (CRSA)-Unité INSERM, Sorbonne Université/Assistance Publique-Hôpitaux de Paris (AP-HP)/Hôpital Trousseau, Paris, France.
Sweeney C; Medical Research Council Molecular Haematology Unit (MRC MHU), Biomedical Research Centre (BRC) Hematology Theme, Oxford Biomedical Research Centre, Oxford Centre for Haematology, Weatherall Institute of Molecular Medicine (WIMM), Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
De Mas V; Team 16, Hematology Laboratory, Center of Research of Cancerology of Toulouse, U1037, INSERM/Institut Universitaire du Cancer de Toulouse (IUCT) Oncopole, Toulouse, France.
Leite B; Genomic Platform, Unité Mixte de Service - Analyse Moléculaire, Modélisation et Imagerie de la maladie Cancéreuse (UMS AMMICA), Gustave Roussy/Université Paris-Saclay, Villejuif, France.
Kadri Z; Division of Innovative Therapies, UMR-1184, Immunologie des Maladies Virales, Auto-immunes, Hématologiques et Bactériennes (IMVA-HB) and Infectious Disease Models and Innovative Therapies (IDMIT) Center, CEA/INSERM/Paris-Saclay University, Fontenay-aux-Roses, France.
Malinge S; Unité 1170 (U1170), INSERM, Gustave Roussy, Université Paris Diderot, Villejuif, France.; Telethon Kids Institute, Perth Children's Hospital, Nedlands, WA, Australia.
de Botton S; Unité 1170 (U1170), INSERM, Gustave Roussy, Université Paris Diderot, Villejuif, France.; Equipe Labellisée Ligue Nationale Contre le Cancer, Paris, France.
Micol JB; Unité 1170 (U1170), INSERM, Gustave Roussy, Université Paris Diderot, Villejuif, France.
Kile B; Australian Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia.
Carmichael CL; Australian Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia.
Iacobucci I; Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN.
Mullighan CG; Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN.; Hematological Malignancies Program, St. Jude Children's Research Hospital, Memphis, TN.
Carroll M; Division of Hematology and Oncology, University of Pennsylvania, PA.
Valent P; Division of Hematology and Hemostaseology, Department of Internal Medicine I and.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
Bernard OA; Unité 1170 (U1170), INSERM, Gustave Roussy, Université Paris Diderot, Villejuif, France.; Equipe Labellisée Ligue Nationale Contre le Cancer, Paris, France.
Delabesse E; Team 16, Hematology Laboratory, Center of Research of Cancerology of Toulouse, U1037, INSERM/Institut Universitaire du Cancer de Toulouse (IUCT) Oncopole, Toulouse, France.
Vyas P; Medical Research Council Molecular Haematology Unit (MRC MHU), Biomedical Research Centre (BRC) Hematology Theme, Oxford Biomedical Research Centre, Oxford Centre for Haematology, Weatherall Institute of Molecular Medicine (WIMM), Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
Birnbaum D; U1068 and.; UMR7258, Centre de Recherche en Cancérologie de Marseille, Centre National de la Recherche Scientifique (CNRS)/INSERM/Institut Paoli Calmettes/Aix-Marseille Université, Marseille, France.
Anguita E; Hematology Department.; Instituto de Medicina de Laboratorio (IML), and.; Instituto de Investigación Sanitaria San Carlos, (IdISSC), Hospital Clínico San Carlos (HCSC), Madrid, Spain; and.; Department of Medicine, Universidad Complutense de Madrid (UCM), Madrid, Spain.
Garçon L; Equipe d'Accueil (EA) 4666, Hématopoïèse et Immunologie (HEMATIM), Université de Picardie Jules Verne (UPJV), Amiens, France.; Service Hématologie Biologique, Centre Hospitalier Universitaire (CHU) Amiens, Amiens, France.
Soler E; IGMM, University of Montpellier, CNRS, Montpellier, France.; Université de Paris, Laboratory of Excellence GR-Ex, Paris, France.
Schwaller J; University Children's Hospital Beider Basel (UKBB), Basel, Switzerland.; Department of Biomedicine, University of Basel, Basel, Switzerland.
Mercher T; Unité 1170 (U1170), INSERM, Gustave Roussy, Université Paris Diderot, Villejuif, France.; Equipe Labellisée Ligue Nationale Contre le Cancer, Paris, France.
Pokaż więcej
Źródło :
Blood [Blood] 2020 Aug 06; Vol. 136 (6), pp. 698-714.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Transcriptome*
Leukemia, Erythroblastic, Acute/*genetics
Neoplasm Proteins/*physiology
Transcription Factors/*physiology
Adult ; Animals ; Cell Transformation, Neoplastic/genetics ; DNA-Binding Proteins/deficiency ; DNA-Binding Proteins/genetics ; DNA-Binding Proteins/physiology ; Erythroblasts/metabolism ; Erythropoiesis/genetics ; Female ; GATA1 Transcription Factor/deficiency ; GATA1 Transcription Factor/genetics ; Gene Knock-In Techniques ; Genetic Heterogeneity ; Hematopoietic Stem Cells/metabolism ; Humans ; Male ; Mice ; Mice, Inbred C57BL ; Mice, Inbred NOD ; Mice, Transgenic ; Middle Aged ; Mutation ; Neoplasm Proteins/genetics ; Neoplastic Stem Cells/metabolism ; Proto-Oncogene Proteins/deficiency ; Proto-Oncogene Proteins/genetics ; Proto-Oncogene Proteins/physiology ; RNA-Seq ; Radiation Chimera ; Repressor Proteins/genetics ; Repressor Proteins/physiology ; Transcription Factors/genetics ; Transcriptional Regulator ERG/genetics ; Transcriptional Regulator ERG/physiology ; Whole Exome Sequencing ; Young Adult
SCR Disease Name :
Acute erythroleukemia
Czasopismo naukowe
Tytuł :
A splenic lymphoma/leukemia with a spontaneous blast decrease without treatment.
Autorzy :
Friedrich C; Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris.
Barreau S; Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris.
Pokaż więcej
Źródło :
Blood [Blood] 2020 Jul 02; Vol. 136 (1), pp. 148.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Leukemia-Lymphoma, Adult T-Cell/*blood
Leukemic Infiltration/*pathology
Neoplastic Stem Cells/*pathology
Spleen/*pathology
Adult ; Humans ; Leukemia-Lymphoma, Adult T-Cell/complications ; Leukemia-Lymphoma, Adult T-Cell/pathology ; Lymphocyte Count ; Male ; Remission, Spontaneous ; Rupture, Spontaneous ; Splenic Rupture/etiology
Czasopismo naukowe
Tytuł :
Calreticulin haploinsufficiency augments stem cell activity and is required for onset of myeloproliferative neoplasms in mice.
Autorzy :
Shide K; Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki Japan.
Kameda T; Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki Japan.
Kamiunten A; Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki Japan.
Ozono Y; Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki Japan.
Tahira Y; Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki Japan.
Yokomizo-Nakano T; Laboratory of Transcriptional Regulation in Leukemogenesis, International Research Center for Medical Sciences (IRCMS), Kumamoto University, Kumamoto, Japan.
Kubota S; Laboratory of Transcriptional Regulation in Leukemogenesis, International Research Center for Medical Sciences (IRCMS), Kumamoto University, Kumamoto, Japan.
Ono M; Division of Chemotherapy and Clinical Research, National Cancer Center Research Institute, Tokyo, Japan; and.
Ikeda K; Department of Blood Transfusion and Transplantation Immunology, Fukushima Medical University, Fukushima, Japan.
Sekine M; Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki Japan.
Akizuki K; Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki Japan.
Nakamura K; Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki Japan.
Hidaka T; Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki Japan.
Kubuki Y; Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki Japan.
Iwakiri H; Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki Japan.
Hasuike S; Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki Japan.
Nagata K; Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki Japan.
Sashida G; Laboratory of Transcriptional Regulation in Leukemogenesis, International Research Center for Medical Sciences (IRCMS), Kumamoto University, Kumamoto, Japan.
Shimoda K; Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki Japan.
Pokaż więcej
Źródło :
Blood [Blood] 2020 Jul 02; Vol. 136 (1), pp. 106-118.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Calreticulin/*physiology
Myeloproliferative Disorders/*etiology
Stem Cells/*pathology
Animals ; Bone Marrow/pathology ; Calreticulin/deficiency ; Calreticulin/genetics ; Cell Self Renewal ; Erythropoiesis ; Genotype ; Hematopoiesis, Extramedullary ; Hematopoietic Stem Cells/pathology ; Mice ; Mice, Transgenic ; Myeloproliferative Disorders/pathology ; Neoplastic Stem Cells/pathology ; Sequence Deletion ; Transcriptome
Czasopismo naukowe
Tytuł :
Genetics of progression from MDS to secondary leukemia.
Autorzy :
Menssen AJ; Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO; and.
Walter MJ; Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO; and.; Siteman Cancer Center, Washington University, St. Louis, MO.
Pokaż więcej
Źródło :
Blood [Blood] 2020 Jul 02; Vol. 136 (1), pp. 50-60.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Leukemia, Myeloid, Acute/*genetics
Myelodysplastic Syndromes/*genetics
Cell Count ; Clonal Evolution ; DNA Methylation/drug effects ; DNA Mutational Analysis ; Disease Progression ; Epigenesis, Genetic ; Hematopoietic Stem Cells/pathology ; Humans ; Lenalidomide/pharmacology ; Lenalidomide/therapeutic use ; Leukemia, Myeloid, Acute/etiology ; Leukemia, Myeloid, Acute/prevention & control ; Mutation ; Myelodysplastic Syndromes/drug therapy ; Myelodysplastic Syndromes/pathology ; Myelopoiesis ; Neoplastic Stem Cells/pathology ; Prognosis ; Tumor Burden ; Whole Exome Sequencing ; Whole Genome Sequencing
Czasopismo naukowe
Tytuł :
PPM1D -truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells.
Autorzy :
Kahn JD; Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.; Broad Institute of MIT and Harvard, Cambridge, MA.; Netherlands Cancer Institute, Amsterdam, The Netherlands.
Miller PG; Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.; Broad Institute of MIT and Harvard, Cambridge, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Silver AJ; Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Sellar RS; Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.; Broad Institute of MIT and Harvard, Cambridge, MA.; UCL Cancer Institute, University College London, London, United Kingdom.
Bhatt S; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Gibson C; Broad Institute of MIT and Harvard, Cambridge, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
McConkey M; Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Adams D; Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Mar B; Broad Institute of MIT and Harvard, Cambridge, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Mertins P; Proteomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA.; Proteomics Platform, Max Delbruck Center for Molecular Medicine in the Helmholtz Society, Berlin, Germany.; Berlin Institute of Health, Berlin, Germany.
Fereshetian S; Proteomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA.
Krug K; Proteomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA.
Zhu H; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Letai A; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Carr SA; Broad Institute of MIT and Harvard, Cambridge, MA.
Doench J; Genetic Perturbation Platform, Broad Institute of MIT and Harvard, Cambridge, MA; and.
Jaiswal S; Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.; Broad Institute of MIT and Harvard, Cambridge, MA.; Department of Pathology, School of Medicine, Stanford University, Stanford, CA.
Ebert BL; Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.; Broad Institute of MIT and Harvard, Cambridge, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Pokaż więcej
Źródło :
Blood [Blood] 2018 Sep 13; Vol. 132 (11), pp. 1095-1105. Date of Electronic Publication: 2018 Jun 28.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Base Sequence*
Drug Resistance, Neoplasm*/drug effects
Drug Resistance, Neoplasm*/genetics
Hematologic Neoplasms*/drug therapy
Hematologic Neoplasms*/enzymology
Hematologic Neoplasms*/genetics
Hematologic Neoplasms*/pathology
Myeloproliferative Disorders*/drug therapy
Myeloproliferative Disorders*/enzymology
Myeloproliferative Disorders*/genetics
Myeloproliferative Disorders*/pathology
Neoplasm Proteins*/antagonists & inhibitors
Neoplasm Proteins*/genetics
Neoplasm Proteins*/metabolism
Protein Phosphatase 2C*/antagonists & inhibitors
Protein Phosphatase 2C*/genetics
Protein Phosphatase 2C*/metabolism
Sequence Deletion*
Enzyme Inhibitors/*pharmacology
Hematopoietic Stem Cells/*enzymology
Neoplastic Stem Cells/*enzymology
CRISPR-Cas Systems ; Cell Line, Tumor ; Hematopoietic Stem Cells/pathology ; Humans ; Neoplastic Stem Cells/pathology
Czasopismo naukowe
Tytuł :
Single-cell approaches identify the molecular network driving malignant hematopoietic stem cell self-renewal.
Autorzy :
Shepherd MS; Wellcome MRC Cambridge Stem Cell Institute and.; Department of Haematology, University of Cambridge, United Kingdom.
Li J; Wellcome MRC Cambridge Stem Cell Institute and.; Department of Haematology, University of Cambridge, United Kingdom.
Wilson NK; Wellcome MRC Cambridge Stem Cell Institute and.; Department of Haematology, University of Cambridge, United Kingdom.
Oedekoven CA; Wellcome MRC Cambridge Stem Cell Institute and.; Department of Haematology, University of Cambridge, United Kingdom.
Li J; Wellcome MRC Cambridge Stem Cell Institute and.; Department of Haematology, University of Cambridge, United Kingdom.
Belmonte M; Wellcome MRC Cambridge Stem Cell Institute and.; Department of Haematology, University of Cambridge, United Kingdom.
Fink J; Wellcome MRC Cambridge Stem Cell Institute and.; Department of Haematology, University of Cambridge, United Kingdom.
Prick JCM; Wellcome MRC Cambridge Stem Cell Institute and.; Department of Haematology, University of Cambridge, United Kingdom.
Pask DC; Wellcome MRC Cambridge Stem Cell Institute and.; Department of Haematology, University of Cambridge, United Kingdom.
Hamilton TL; Wellcome MRC Cambridge Stem Cell Institute and.; Department of Haematology, University of Cambridge, United Kingdom.
Loeffler D; Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland; and.
Rao A; La Jolla Institute and Department of Pharmacology, University of California, San Diego, La Jolla, CA.
Schröder T; Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland; and.
Göttgens B; Wellcome MRC Cambridge Stem Cell Institute and.; Department of Haematology, University of Cambridge, United Kingdom.
Green AR; Wellcome MRC Cambridge Stem Cell Institute and.; Department of Haematology, University of Cambridge, United Kingdom.; Department of Haematology, Addenbrooke's Hospital, Hills Road, Cambridge, United Kingdom.
Kent DG; Wellcome MRC Cambridge Stem Cell Institute and.; Department of Haematology, University of Cambridge, United Kingdom.
Pokaż więcej
Źródło :
Blood [Blood] 2018 Aug 23; Vol. 132 (8), pp. 791-803. Date of Electronic Publication: 2018 Jul 10.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Cell Self Renewal*
Gene Expression Regulation, Neoplastic*
Mutation, Missense*
Hematologic Neoplasms/*metabolism
Hematopoietic Stem Cells/*metabolism
Janus Kinase 2/*metabolism
Myeloproliferative Disorders/*metabolism
Neoplasm Proteins/*metabolism
Neoplastic Stem Cells/*metabolism
Amino Acid Substitution ; Animals ; Hematologic Neoplasms/genetics ; Hematologic Neoplasms/pathology ; Hematopoietic Stem Cells/pathology ; Janus Kinase 2/genetics ; Mice ; Mice, Transgenic ; Myeloproliferative Disorders/genetics ; Myeloproliferative Disorders/pathology ; Neoplasm Proteins/genetics ; Neoplastic Stem Cells/pathology
Czasopismo naukowe
Tytuł :
hsa-mir183/EGR1 -mediated regulation of E2F1 is required for CML stem/progenitor cell survival.
Autorzy :
Pellicano F; Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, United Kingdom.
Park L; Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, United Kingdom.
Hopcroft LEM; Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, United Kingdom.
Shah MM; Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, United Kingdom.
Jackson L; Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, United Kingdom.
Scott MT; Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, United Kingdom.
Clarke CJ; Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, United Kingdom.
Sinclair A; Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, United Kingdom.
Abraham SA; Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, United Kingdom.
Hair A; Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, United Kingdom.
Helgason GV; Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, United Kingdom.
Aspinall-O'Dea M; Stem Cell and Leukaemia Proteomics Laboratory, Faculty Institute of Cancer Sciences, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom.
Bhatia R; Division of Hematology and Oncology, School of Medicine, The University of Alabama at Birmingham, Birmingham, AL.
Leone G; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; and.
Kranc KR; MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, United Kingdom.
Whetton AD; Stem Cell and Leukaemia Proteomics Laboratory, Faculty Institute of Cancer Sciences, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom.
Holyoake TL; Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, United Kingdom.
Pokaż więcej
Źródło :
Blood [Blood] 2018 Apr 05; Vol. 131 (14), pp. 1532-1544. Date of Electronic Publication: 2018 Feb 05.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Gene Expression Regulation, Leukemic*
Up-Regulation*
E2F1 Transcription Factor/*biosynthesis
Early Growth Response Protein 1/*metabolism
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*metabolism
MicroRNAs/*metabolism
Neoplasm Proteins/*metabolism
Neoplastic Stem Cells/*metabolism
RNA, Neoplasm/*metabolism
Animals ; Cell Proliferation ; Cell Survival ; E2F1 Transcription Factor/genetics ; Early Growth Response Protein 1/genetics ; Female ; Humans ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology ; Male ; Mice, Knockout ; MicroRNAs/genetics ; Neoplasm Proteins/genetics ; Neoplastic Stem Cells/pathology ; RNA, Neoplasm/genetics ; Signal Transduction
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies